Skip to content

Efficacy and safety of esketamine and fentanyl combined with propofol in painless gastroenteroscopy anesthesia

Efficacy and safety of esketamine and fentanyl combined with propofol in painless gastroenteroscopy anesthesia

Status
Active, not recruiting
Phases
Phase 1
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2200063215
Enrollment
Unknown
Registered
2022-09-01
Start date
2022-09-01
Completion date
Unknown
Last updated
2023-04-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastroenteroscopy anesthesia

Interventions

Experimental group:Esketamine + Propofol
Conrol group:Fentanyl + Propofol

Sponsors

West China School of Public Health and West China Fourth Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. The patient was confirmed to be able to participate in painless gastroenteroscopy by the expert consensus opinion on sedation and anesthesia in the diagnosis and treatment of digestive endoscopy in China, which met the relevant standards required for anesthesia; 2. Have basic cognitive awareness, can cooperate with the relevant anesthesia treatment; 3. The functions of heart and lung, liver and kidney were in normal state; 4. Aged 18-60 years; 5. The American Society of Anesthesiologists' classification is grade I or II; 6. Patients and their family members clearly knew the purpose and operation process of the study, and signed the informed letter by the patients themselves, agreeing to participate in the study.

Exclusion criteria

Exclusion criteria: 1. Complicated with severe anemia, acute colitis, congenital gastrointestinal malformation, extensive adhesion in the abdominal cavity and other diseases; 2. Women during menstruation, lactation and pregnancy; 3. Allergic to drugs used in the study: propofol and esketamine; 4. Patients with severe hypertension, coronary heart disease, asthma, systemic infectious diseases, nervous system diseases or medical history; 5. Patients with drug dependence or a history of drug dependence.

Design outcomes

Primary

MeasureTime frame
propofol;

Countries

China

Contacts

Public ContactQing Ailing

West China Fourth Hospital, Sichuan University

mail2qing@163.cm+86 15802809342

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026